Treatment of essential hypertension.
Olneda is indicated in adult patients whose blood pressure is not adequately controlled on
olmesartan medoxomil or amlodipine monotherapy (see section 4.2 and section 5.1).

Adults
The recommended dosage of Olnedais 1 tablet per day.
Olneda 20 mg/5 mg may be administered in patients whose blood pressure is not adequately
controlled by 20 mg olmesartan medoxomil or 5 mg amlodipine alone.
Olneda 40 mg/5 mg may be administered in patients whose blood pressure is not adequately
controlled by Olneda 20 mg/5 mg.
Olneda 40 mg/10 mg may be administered in patients whose blood pressure is not adequately
controlled by Olneda 40 mg/5 mg
Olneda 40 mg/20 mg may be administered in patients whose blood pressure is not adequately
controlled by Olneda 40 mg/10 mg
A step-wise titration of the dosage of the individual components is recommended before changing
to the fixed combination. When clinically appropriate, direct change from monotherapy to the
fixed combination may be considered.

For convenience, patients receiving olmesartan medoxomil and amlodipine from separate tablets
may be switched to Olneda tablets containing the same component doses.
Olneda can be taken with or without food.
Elderly (age 65 years or over)
No adjustment of the recommended dose is generally required for elderly people but increase of
the dosage should take place with care (see sections 4.4 and 5.2).
If up-titration to the maximum dose of 40 mg olmesartan medoxomil daily is required, blood
pressure should be closely monitored.
Renal impairment
The maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment
(creatinine clearance of 20 – 60 mL/min) is 20 mg olmesartan medoxomil once daily, owing to
limited experience of higher dosages in this patient group. The use of Olneda in patients with
severe renal impairment (creatinine clearance < 20 mL/min) is not recommended (see 4.4, 5.2).
Monitoring of potassium levels and creatinine is advised in patients with moderate renal
impairment.
Hepatic impairment
Olnedashould be used with caution in patients with mild to moderate hepatic impairment (see
sections 4.4, 5.2).
In patients with moderate hepatic impairment, an initial dose of 10 mg olmesartan medoxomil once
daily is recommended and the maximum dose should not exceed 20 mg once daily. Close
monitoring of blood pressure and renal function is advised in hepatically-impaired patients who are already receiving diuretics and/or other antihypertensive agents. There is no experience of
olmesartan medoxomil in patients with severe hepatic impairment.
As with all calcium antagonists, amlodipine's half-life is prolonged in patients with impaired liver
function and dosage recommendations have not been established. Olneda should therefore be
administered with caution in these patients. The pharmacokinetics of amlodipine have not been
studied in severe hepatic impairment. Amlodipine should be initiated at the lowest dose and titrated
slowly in patients with impaired liver function. Use of Olneda in patients with severe hepatic
impairment is contraindicated (see section 4.3).
Paediatric population
The safety and efficacy of Olneda in children and adolescents below 18 years has not been
established. No data are available.
Method of administration:
The tablet should be swallowed with a sufficient amount of fluid (e.g. one glass of water). The
tablet should not be chewed and should be taken at the same time each day.

Hypersensitivity to the active substances, to dihydropyridine derivatives or to any of the excipients listed in section 6.1. Second and third trimesters of pregnancy (see sections 4.4 and 4.6). Severe hepatic insufficiency and biliary obstruction (see section 5.2). The concomitant use of Olneda with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m2) (see sections 4.5 and 5.1). Due to the component amlodipine Olneda is also contraindicated in patients with: - severe hypotension. - shock (including cardiogenic shock). - obstruction of the outflow tract of the left ventricle (e.g. high grade aortic stenosis). - haemodynamically unstable heart failure after acute myocardial infarction.

Patients with hypovolaemia or sodium depletion:
Symptomatic hypotension may occur in patients who are volume and/or sodium depleted by
vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting, especially after the first
dose. Correction of this condition prior to administration of Olneda or close medical supervision
at the start of the treatment is recommended.
Other conditions with stimulation of the renin-angiotensin-aldosterone system:
In patients whose vascular tone and renal function depend predominantly on the activity of the
renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or
underlying renal disease, including renal artery stenosis), treatment with other medicinal products
that affect this system, such as angiotensin II receptor antagonists, has been associated with acute
hypotension, azotaemia, oliguria or, rarely, acute renal failure.
Renovascular hypertension:
There is an increased risk of severe hypotension and renal insufficiency when patients with
bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated
with medicinal products that affect the renin-angiotensin-aldosterone system.
Renal impairment and kidney transplantation:
When Olneda is used in patients with impaired renal function, periodic monitoring of serum
potassium and creatinine levels is recommended. Use of Olneda is not recommended in patients with severe renal impairment (creatinine clearance < 20 mL/min) (see sections 4.2, 5.2). There is
no experience of the administration of Olneda in patients with a recent kidney transplant or in
patients with end-stage renal impairment (i.e. creatinine clearance < 12 mL/min).
Dual blockade of the renin-angiotensin-aldosterone system (RAAS):
There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or
aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including
acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors,
angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and
5.1).
If dual blockade therapy is considered absolutely necessary, this should only occur under specialist
supervision and subject to frequent close monitoring of renal function, electrolytes and blood
pressure.
ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients
with diabetic nephropathy.
Hepatic impairment:
Exposure to amlodipine and olmesartan medoxomil is increased in patients with hepatic
impairment (see section 5.2). Care should be taken when Olneda is administered in patients with
mild to moderate hepatic impairment. In moderately impaired patients, the dose of olmesartan
medoxomil should not exceed 20 mg (see section 4.2). In patients with impaired hepatic function,
amlodipine should be initiated at the lower end of the dosing range and caution should be used,
both on initial treatment and when increasing the dose. Use of Olneda in patients with severe
hepatic impairment is contraindicated (see section 4.3).

Hyperkalaemia:
As with other angiotensin II antagonists and ACE inhibitors, hyperkalaemia may occur during
treatment, especially in the presence of renal impairment and/or heart failure (see section 4.5).
Close monitoring of serum potassium levels in at-risk patients is recommended.
Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes
containing potassium, or other medicinal products that may increase potassium levels (heparin,
etc.) should be undertaken with caution and with frequent monitoring of potassium levels.
Lithium:
As with other angiotensin II receptor antagonists, the concomitant use of Olneda and lithium is not
recommended (see section 4.5).
Aortic or mitral valve stenosis; obstructive hypertrophic cardiomyopathy:
Due to the amlodipine component of Olneda, as with all other vasodilators, special caution is
indicated in patients suffering from aortic or mitral valve stenosis, or obstructive hypertrophic
cardiomyopathy.
Primary aldosteronism:
Patients with primary aldosteronism generally will not respond to antihypertensive medicinal
products acting through inhibition of the renin-angiotensin system. Therefore, the use of Olneda
is not recommended in such patients.

Heart failure:
As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal
function may be anticipated in susceptible individuals. In patients with severe heart failure whose
renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment
with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has
been associated with oliguria and/or progressive azotaemia and (rarely) with acute renal failure
and/or death.
Patients with heart failure should be treated with caution. In a long-term, placebo controlled study
of amlodipine in patients with severe heart failure (NYHA III and IV), the reported incidence of
pulmonary oedema was higher in the amlodipine group than in the placebo group (see section 5.1).
Calcium channel blockers, including amlodipine, should be used with caution in patients with
congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.
Sprue-like enteropathy:
In very rare cases severe, chronic diarrhoea with substantial weight loss has been reported in
patients taking olmesartan few months to years after drug initiation, possibly caused by a localized
delayed hypersensitivity reaction. Intestinal biopsies of patients often demonstrated villous
atrophy. If a patient develops these symptoms during treatment with olmesartan, and in the absence
of other apparent etiologies, olmesartan treatment should be immediately discontinued and should
not be restarted. If diarrhoea does not improve during the week after the discontinuation, further
specialist (e.g. a gastro-enterologist) advice should be considered.
Ethnic differences:
As with all other angiotensin II antagonists, the blood pressure lowering effect of Olneda can be
somewhat less in black patients than in non-black patients, possibly because of a higher prevalence
of low-renin status in the black hypertensive population.

Elderly:
In the elderly, increase of the dosage should take place with care (see section 5.2).
Pregnancy:
Angiotensin II antagonists should not be initiated during pregnancy. Unless continued angiotensin
II antagonist therapy is considered essential, patients planning pregnancy should be changed to
alternative antihypertensive treatments which have an established safety profile for use in
pregnancy. When pregnancy is diagnosed, treatment with angiotensin II antagonists should be
stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3
and 4.6).
Other:
As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic
heart disease or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke.
This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say
essentially 'sodium-free'.
 

Potential interactions related to the Olneda combination:
To be taken into account with concomitant use
Other antihypertensive agents:
The blood pressure lowering effect of Olneda can be increased by concomitant use of other
antihypertensive medicinal products (e.g. alpha blockers, diuretics).
Potential interactions related to the olmesartan medoxomil component of Olneda:
Concomitant use not recommended ACE-inhibitors, angiotensin II receptor blockers or aliskiren:
Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system
(RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren
is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and
decreased renal function (including acute renal failure) compared to the use of a single RAASacting
agent (see sections 4.3, 4.4 and 5.1).
Medicinal products affecting potassium levels:
Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes
containing potassium or other medicinal products that may increase serum potassium levels (e.g.
heparin, ACE inhibitors) may lead to increases in serum potassium (see section 4.4). If medicinal
products which affect potassium levels are to be prescribed in combination with Olneda,
monitoring of serum potassium levels is recommended.
Lithium:
Reversible increases in serum lithium concentrations and toxicity have been reported during
concomitant administration of lithium with angiotensin converting enzyme inhibitors and, rarely,
with angiotensin II antagonists. Therefore concomitant use of Olneda and lithium is not
recommended (see section 4.4). If concomitant use of Olneda and lithium proves necessary, careful
monitoring of serum lithium levels is recommended.
Concomitant use requiring caution
Non-steroidal anti-inflammatory medicinal products (NSAIDs) including selective COX-2
inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NSAIDs:
When angiotensin II antagonists are administered simultaneously with NSAIDs, attenuation of the
antihypertensive effect may occur. Furthermore, concomitant use of angiotensin II antagonists and NSAIDs may increase the risk of worsening of renal function and may lead to an increase in serum
potassium. Therefore monitoring of renal function at the beginning of such concomitant therapy
is recommended, as well as adequate hydration of the patient.
Bile acid sequestering agent colesevelam:
Concurrent administration of the bile acid sequestering agent colesevelam hydrochloride reduces
the systemic exposure and peak plasma concentration of olmesartan and reduces t1/2.
Administration of olmesartan medoxomil at least 4 hours prior to colesevelam hydrochloride
decreased the drug interaction effect. Administering olmesartan medoxomil at least 4 hours before
the colesevelam hydrochloride dose should be considered (see section 5.2).
Additional information
After treatment with antacid (aluminium magnesium hydroxide), a modest reduction in
bioavailability of olmesartan was observed.
Olmesartan medoxomil had no significant effect on the pharmacokinetics or pharmacodynamics
of warfarin or the pharmacokinetics of digoxin. Coadministration of olmesartan medoxomil with
pravastatin had no clinically relevant effects on the pharmacokinetics of either component in
healthy subjects.
Olmesartan had no clinically relevant inhibitory effects on human cytochrome P450 enzymes
1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4 in vitro, and had no or minimal inducing effects on
rat cytochrome P450 activities. No clinically relevant interactions between olmesartan and
medicinal products metabolised by the above cytochrome P450 enzymes are expected.

Potential interactions related to the amlodipine component of Olneda:
Effects of other medicinal products on amlodipine
CYP3A4 inhibitors:
Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors,
azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may
give rise to significant increase in amlodipine exposure. The clinical translation of these PK
variations may be more pronounced in the elderly. There is an increased risk of hypotension. Close
observation of patients is recommended and dose adjustment may thus be required.
CYP3A4 inducers:
Upon co-administration of known inducers of the CYP3A4, the plasma concentration of
amlodipine may vary. Therefore, blood pressure should be monitored and dose regulation
considered both during and after concomitant medication particularly with strong CYP3A4
inducers (e.g. rifampicin, hypericum perforatum).
Administration of amlodipine with grapefruit or grapefruit juice is not recommended as
bioavailability may be increased in some patients resulting in increased blood pressure lowering
effects.
Dantrolene (infusion): In animals, lethal ventricular fibrillation and cardiovascular collapse are
observed in association with hyperkalaemia after administration of verapamil and intravenous
dantrolene. Due to risk of hyperkalaemia, it is recommended that the co-administration of calcium
channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia
and in the management of malignant hyperthermia.
Effects of amlodipine on other medicinal products
The blood pressure lowering effects of amlodipine adds to the blood pressure-lowering effects of
other antihypertensive agents.

In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin,
digoxin or warfarin.
Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin
resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the
dose of simvastatin in patients on amlodipine to 20 mg daily.
Tacrolimus: There is a risk of increased tacrolimus blood levels when co-administered with
amlodipine. In order to avoid toxicity of tacrolimus, administration of amlodipine in a patient
treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of
tacrolimus when appropriate.
Cyclosporine: In a prospective study in renal transplant patients, an average 40% increase in trough
cyclosporine levels was observed when used concomitantly with amlodipine. The coadministration
of Olneda with cyclosporine may increase exposure to cyclosporine. Monitor
trough cyclosporine levels during concomitant use and cyclosporine dose reductions should be
made as necessary.

There are no data about the use of Olneda in pregnant patients. Animal reproductive toxicity
studies with Olneda have not been performed.
Olmesartan medoxomil (active ingredient of Olneda)
The use of angiotensin II antagonists is not recommended during the first trimester of pregnancy
(see section 4.4). The use of angiotensin II antagonists is contraindicated during the 2nd and 3rd
trimesters of pregnancy (see sections 4.3 and 4.4).
Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE
inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase
in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with
angiotensin II antagonists, similar risks may exist for this class of drugs. Unless continued angiotensin II antagonists therapy is considered essential, patients planning pregnancy should be
changed to alternative anti-hypertensive treatments which have an established safety profile for
use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II antagonists should
be stopped immediately, and, if appropriate, alternative therapy should be started.
Exposure to angiotensin II antagonists therapy during the second and third trimesters is known to
induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification
retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).
Should exposure to angiotensin II antagonists have occurred from the second trimester on,
ultrasound check of renal function and skull is recommended. Infants whose mothers have taken
angiotensin II antagonists should be closely observed for hypotension (see sections 4.3 and 4.4).
Amlodipine (active ingredient of Olneda)
Data on a limited number of exposed pregnancies do not indicate that amlodipine or other calcium
receptor antagonists have a harmful effect on the health of the fetus. However, there may be a risk
of prolonged delivery.
As a consequence, Olneda is not recommended during the first trimester of pregnancy and is
contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).
Breastfeeding
Olmesartan is excreted into the milk of lactating rats. However, it is not known whether olmesartan
passes into human milk.
Amlodipine is excreted in human milk. The proportion of the maternal dose received by the infant
has been estimated with an interquartile range of 3 - 7%, with a maximum of 15%. The effect of
amlodipine on infants is unknown.
During breast-feeding, Olneda is not recommended and alternative treatments with better
established safety profiles during breast-feeding are preferable, especially while nursing a new
born or preterm infant.

Fertility
Reversible biochemical changes in the head of spermatozoa have been reported in some patients
treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of
amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section
5.3).

Olneda can have minor or moderate influence on the ability to drive and use machines.
Dizziness, headache, nausea or fatigue may occasionally occur in patients taking antihypertensive
therapy, which may impair the ability to react. Caution is recommended especially at the start of
treatment.

Very rare (<1/10,000), not known (cannot be estimated from the available data)

 

 

MedDRA System Organ Class	Adverse reactions	Frequency
		Olmesartan/Amlodipine combination	Olmesartan	Amlodipine
Blood and lymphatic system disorders	Leukocytopenia			Very rare
	Thrombocytopenia		Uncommon	Very rare
Immune system disorders	Allergic reaction /Drug hypersensitivity	Rare		Very rare
	Anaphylactic reaction		Uncommon
Metabolism and nutrition disorders	Hyperglycaemia			Very rare
	Hyperkalaemia	Uncommon	Rare
	Hypertriglyceridaemia		Common
	Hyperuricaemia		Common
Psychiatric disorders	Confusion			Rare
	Depression			Uncommon
	Insomnia			Uncommon
	Irritability			Uncommon
	Libido decreased	Uncommon
	Mood changes (including anxiety)			Uncommon
Nervous system disorders	Dizziness	Common	Common	Common
	Dysgeusia			Uncommon
	Headache	Common	Common	Common (especially at the beginning of treatment)
	Hypertonia			Very rare
	Hypoaesthesia	Uncommon		Uncommon
	Lethargy	Uncommon
	Paraesthesia	Uncommon		Uncommon
	Peripheral neuropathy			Very rare
	Postural dizziness	Uncommon
	Sleep disorder			Uncommon
	Somnolence			Common
	Syncope	Rare		Uncommon
	Tremor			Uncommon
	Extrapyramidal disorder			Not known
Eye disorders	Visual disturbance (including diplopia)			Common
Ear and labyrinth disorders	Tinnitus			Uncommon
	Vertigo	Uncommon	Uncommon
Cardiac disorders	Angina pectoris		Uncommon	Uncommon (incl. aggravation of angina pectoris)
	Arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation)			Uncommon
	Myocardial infarction			Very rare
	Palpitations	Uncommon		Common
	Tachycardia	Uncommon
Vascular disorders	Hypotension	Uncommon	Rare	Uncommon
	Orthostatic hypotension	Uncommon
	Flushing	Rare		Common
	Vasculitis			Very rare
Respiratory, thoracic and mediastinal disorders	Bronchitis		Common
	Cough	Uncommon	Common	Uncommon
	Dyspnoea	Uncommon		Common
	Pharyngitis		Common
	Rhinitis		Common	Uncommon
Gastrointestinal disorders	Abdominal pain		Common	Common
	Altered bowel habits (including diarrhoea and constipation)			Common
	Constipation	Uncommon
	Diarrhoea	Uncommon	Common
	Dry mouth	Uncommon		Uncommon
	Dyspepsia	Uncommon	Common	Common
	Gastritis			Very rare
	Gastroenteritis		Common
	Gingival hyperplasia			Very rare
	Nausea	Uncommon	Common	Common
	Pancreatitis			Very rare
	Upper abdominal pain	Uncommon
	Vomiting	Uncommon	Uncommon	Uncommon
	Sprue-like enteropathy (see section 4.4)		Very rare
Hepato-biliary disorders	Hepatic enzymes increased		Common	Very rare (mostly consistent with cholestasis)
	Hepatitis			Very rare
	Jaundice			Very rare
Skin and subcutaneous tissue disorders	Alopecia			Uncommon
	Angioneurotic oedema		Rare	Very rare
	Allergic dermatitis		Uncommon
	Erythema multiforme			Very rare
	Exanthema		Uncommon	Uncommon
	Exfoliative dermatitis			Very rare
	Hyperhydrosis			Uncommon
	Photosensitivity			Very rare
	Pruritus		Uncommon	Uncommon
	Purpura			Uncommon
	Quincke oedema			Very rare
	Rash	Uncommon	Uncommon	Uncommon
	Skin discoloration			Uncommon
	Stevens-Johnson syndrome			Very rare
	Toxic Epidermal Necrolysis			Not known
	Urticaria	Rare	Uncommon	Uncommon
Musculoskeletal and connective tissue disorders	Ankle swelling			Common
	Arthralgia			Uncommon
	Arthritis		Common
	Back pain	Uncommon	Common	Uncommon
	Muscle spasm	Uncommon	Rare	Common
	Myalgia		Uncommon	Uncommon
	Pain in extremity	Uncommon
	Skeletal pain		Common
Renal and urinary disorders	Acute renal failure		Rare
	Haematuria		Common
	Increased urinary frequency			Uncommon
	Micturition disorder			Uncommon
	Nocturia			Uncommon
	Pollakiuria	Uncommon
	Renal insufficiency		Rare
	Urinary tract infection		Common
Reproductive system and breast disorders	Erectile dysfunction/impotence	Uncommon		Uncommon
	Gynecomastia			Uncommon
General disorders and administration site conditions	Asthenia	Uncommon	Uncommon	Common
	Chest pain		Common	Uncommon
	Face oedema	Rare	Uncommon
	Fatigue	Common	Common	Common
	Influenza-like symptoms		Common
	Lethargy		Rare
	Malaise		Uncommon	Uncommon
	Oedema	Common		Very common
	Pain		Common	Uncommon
	Peripheral oedema	Common	Common
	Pitting oedema	Common
Investigations	Blood creatinine increased	Uncommon	Rare
	Blood creatine phosphokinase increased		Common
	Blood potassium decreased	Uncommon
	Blood urea increased		Common
	Blood uric acid increased	Uncommon
	Gamma glutamyl transferase increased	Uncommon
	Weight decrease			Uncommon
	Weight increase			Uncommon

Single cases of rhabdomyolysis have been reported in temporal association with the intake of
angiotensin II receptor blockers. Single cases of extrapyramidal syndrome have been reported in
patients treated with amlodipine.
To reports any side effect(s):
 Saudi Arabia
-The National Pharmacovigilance and Drug Safety Centre (NPC)
Fax: +966-11-205-7662
Call NPC at +966-11-2038222, Exts: 2317--2356-2340.
Toll free phone: 19999
E-mail: npc.drug@sfda.gov.sa
Website: www.sfda.gov.sa/npc
• Other GCC States:
Please contact the relevant competent authority.

Symptoms:
There is no experience of overdose with Olneda. The most likely effects of olmesartan medoxomil
overdosage are hypotension and tachycardia; bradycardia could be encountered if parasympathetic
(vagal) stimulation occurred. Amlodipine overdosage can be expected to lead to excessive
peripheral vasodilatation with marked hypotension and possibly a reflex tachycardia. Marked and
potentially prolonged systemic hypotension up to and including shock with fatal outcome has been
reported.
Treatment:
If intake is recent, gastric lavage may be considered. In healthy subjects, the administration of
activated charcoal immediately or up to 2 hours after ingestion of amlodipine has been shown to
reduce substantially the absorption of amlodipine.
Clinically significant hypotension due to an overdose of Olnedarequires active support of the
cardiovascular system, including close monitoring of heart and lung function, elevation of the
extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be
helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to
its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium
channel blockade. Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.
The dialysability of olmesartan is unknown.

Pharmacotherapeutic group: Angiotensin II antagonists and calcium channel blockers,
ATC code C09DB02.
Mechanism of action
Olneda is a combination of an angiotensin II receptor antagonist, olmesartan medoxomil, and a
calcium channel blocker, amlodipine besilate. The combination of these active ingredients has an
additive antihypertensive effect, reducing blood pressure to a greater degree than either component
alone.
Clinical efficacy and safety
Olneda
In an 8-week, double-blind, randomised, placebo-controlled factorial design study in 1940 patients
(71% Caucasian and 29% non-Caucasian patients), treatment with each combination dose of
Olnedaresulted in significantly greater reductions in diastolic and systolic blood pressures than the
respective monotherapy components. The mean change in systolic/diastolic blood pressure was
dose-dependent: -24/-14 mmHg (20 mg/5 mg combination), -25/-16 mmHg (40 mg/5 mg
combination) and -30/-19 mmHg (40 mg/10 mg combination).
Olneda40 mg/5 mg reduced seated systolic/diastolic blood pressure by an additional 2.5/1.7 mmHg
over Olneda20 mg/5 mg. Similarly Olneda40 mg/10 mg reduced seated systolic/diastolic blood
pressure by an additional 4.7/3.5 mmHg over Olneda40 mg/5 mg.
The proportions of patients reaching blood pressure goal (< 140/90 mmHg for non-diabetic
patients and < 130/80 mmHg for diabetic patients) were 42.5%, 51.0% and 49.1% for Olneda20
mg/5 mg, 40 mg/5 mg and 40 mg/10 mg respectively.
The majority of the antihypertensive effect of Olneda was generally achieved within the first 2
weeks of therapy.

A second double-blind, randomised, placebo-controlled study evaluated the effectiveness of
adding amlodipine to the treatment in Caucasian patients whose blood pressure was inadequately
controlled by 8 weeks of monotherapy with 20 mg olmesartan medoxomil.
In patients who continued to receive only 20 mg olmesartan medoxomil, systolic/diastolic blood
pressure was reduced by -10.6/ -7.8 mmHg after a further 8 weeks. The addition of 5 mg
amlodipine for 8 weeks resulted in a reduction in systolic/diastolic blood pressure of -16.2/-10.6
mmHg (p = 0.0006).
The proportion of patients reaching blood pressure goal (< 140/90 mmHg for non-diabetic patients
and < 130/80 mmHg for diabetic patients) was 44.5% for the 20 mg/5 mg combination compared
to 28.5% for 20 mg olmesartan medoxomil.
A further study evaluated the addition of various doses of olmesartan medoxomil in Caucasian
patients whose blood pressure was not adequately controlled by 8 weeks of monotherapy with 5
mg amlodipine.
In patients who continued to receive only 5 mg amlodipine, systolic/diastolic blood pressure was
reduced by -9.9/ -5.7 mmHg after a further 8 weeks. The addition of 20 mg olmesartan medoxomil
resulted in a reduction in systolic/diastolic blood pressure of -15.3/-9.3 mmHg and the addition of
40 mg olmesartan medoxomil resulted in a reduction in systolic/diastolic blood pressure of -16.7/-
9.5 mmHg (p < 0.0001).
The proportions of patients reaching blood pressure goal (< 140/90 mmHg for non-diabetic
patients and < 130/80 mmHg for diabetic patients) was 29.9% for the group who continued to
receive 5 mg amlodipine alone, 53.5% for Olneda20 mg/5 mg and 50.5% for Olneda40 mg/5 mg.
Randomised data in uncontrolled hypertensive patients, comparing the use of medium dose Olneda
combination therapy versus escalation to top dose monotherapy of amlodipine or olmesartan, are
not available.
The three studies performed confirmed that the blood pressure lowering effect of Olneda once
daily was maintained throughout the 24-hour dose interval, with trough-to-peak ratios of 71% to 82% for systolic and diastolic response and with 24-hour effectiveness being confirmed by
ambulatory blood pressure monitoring.
The antihypertensive effect of Olneda was similar irrespective of age and gender, and was similar
in patients with and without diabetes.
In two open-label, non-randomised extension studies, sustained efficacy using Olneda40 mg/5 mg
was demonstrated at one year for 49 - 67% of patients.
Olmesartan medoxomil (active ingredient of Olneda)
The olmesartan medoxomil component of Olnedais a selective angiotensin II type 1 (AT1) receptor
antagonist. Olmesartan medoxomil is rapidly converted to the pharmacologically active
metabolite, olmesartan. Angiotensin II is the primary vasoactive hormone of the renin-angiotensinaldosterone
system and plays a significant role in the pathophysiology of hypertension. The effects
of angiotensin II include vasoconstriction, stimulation of the synthesis and release of aldosterone,
cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor and
aldosterone-secreting effects of angiotensin II by blocking its binding to the AT1 receptor in
tissues including vascular smooth muscle and the adrenal gland. The action of olmesartan is
independent of the source or route of synthesis of angiotensin II. The selective antagonism of the
angiotensin II (AT1) receptors by olmesartan results in increases in plasma renin levels and
angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations.
In hypertension, olmesartan medoxomil causes a dose-dependent, long-lasting reduction in arterial
blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during
long-term treatment, or of rebound hypertension after abrupt cessation of therapy.
Following once daily administration to patients with hypertension, olmesartan medoxomil
produces an effective and smooth reduction in blood pressure over the 24 hour dose interval. Once
daily dosing produced similar decreases in blood pressure as twice daily dosing at the same total
daily dose.

With continuous treatment, maximum reductions in blood pressure are achieved by 8 weeks after
the initiation of therapy, although a substantial proportion of the blood pressure lowering effect is
already observed after 2 weeks of treatment.
The effect of olmesartan medoxomil on mortality and morbidity is not yet known.
The Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study in
4447 patients with type 2 diabetes, normo-albuminuria and at least one additional cardiovascular
risk factor, investigated whether treatment with olmesartan could delay the onset of
microalbuminuria. During the median follow-up duration of 3.2 years, patients received either
olmesartan or placebo in addition to other antihypertensive agents, except ACE inhibitors or
ARBs.
For the primary endpoint, the study demonstrated a significant risk reduction in the time to onset
of microalbuminuria, in favour of olmesartan. After adjustment for BP differences this risk
reduction was no longer statistically significant. 8.2% (178 of 2160) of the patients in the
olmesartan group and 9.8% (210 of 2139) in the placebo group developed microalbuminuria.
For the secondary endpoints, cardiovascular events occurred in 96 patients (4.3%) with olmesartan
and in 94 patients (4.2%) with placebo. The incidence of cardiovascular mortality was higher with
olmesartan compared to placebo treatment (15 patients (0.7%) vs. 3 patients (0.1%)), despite
similar rates for non-fatal stroke (14 patients (0.6%) vs. 8 patients (0.4%)), non-fatal myocardial
infarction (17 patients (0.8%) vs. 26 patients (1.2%)) and non-cardiovascular mortality (11 patients
(0.5%) vs. 12 patients (0.5%)). Overall mortality with olmesartan was numerically increased (26
patients (1.2%) vs. 15 patients (0.7%)), which was mainly driven by a higher number of fatal
cardiovascular events.
The Olmesartan Reducing Incidence of End-stage Renal Disease in Diabetic Nephropathy Trial
(ORIENT) investigated the effects of olmesartan on renal and cardiovascular outcomes in 577
randomized Japanese and Chinese type 2 diabetic patients with overt nephropathy. During a
median follow-up of 3.1 years, patients received either olmesartan or placebo in addition to other
antihypertensive agents including ACE inhibitors.

The primary composite endpoint (time to first event of the doubling of serum creatinine, end-stage
renal disease, all-cause death) occurred in 116 patients in the olmesartan group (41.1%) and 129
patients in the placebo group (45.4%) (HR 0.97 (95% CI 0.75 to 1.24); p=0.791). The composite
secondary cardiovascular endpoint occurred in 40 olmesartan-treated patients (14.2%) and 53
placebo-treated patients (18.7%). This composite cardiovascular endpoint included cardiovascular
death in 10 (3.5%) patients receiving olmesartan versus 3 (1.1%) receiving placebo, overall
mortality 19 (6.7%) versus 20 (7.0%), non-fatal stroke 8 (2.8%) versus 11 (3.9%) and non-fatal
myocardial infarction 3 (1.1%) versus 7 (2.5%), respectively.
Amlodipine (active ingredient of Olneda)
The amlodipine component of Olneda is a calcium channel blocker that inhibits the transmembrane
influx of calcium ions through the potential-dependent L-type channels into the heart and smooth
muscle. Experimental data indicate that amlodipine binds to both dihydropyridine and nondihydropyridine
binding sites. Amlodipine is relatively vessel-selective, with a greater effect on
vascular smooth muscle cells than on cardiac muscle cells. The antihypertensive effect of
amlodipine derives from a direct relaxant effect on arterial smooth muscle, which leads to a
lowering of peripheral resistance and hence of blood pressure.
In hypertensive patients, amlodipine causes a dose-dependent, long-lasting reduction in arterial
blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during
long-term treatment, or of rebound hypertension after abrupt cessation of therapy.
Following administration of therapeutic doses to patients with hypertension, amlodipine produces
an effective reduction in blood pressure in the supine, sitting and standing positions. Chronic use
of amlodipine is not associated with significant changes in heart rate or plasma catecholamine
levels. In hypertensive patients with normal renal function, therapeutic doses of amlodipine reduce
renal vascular resistance and increase glomerular filtration rate and effective renal plasma flow,
without changing filtration fraction or proteinuria.
In haemodynamic studies in patients with heart failure and in clinical studies based on exercise
tests in patients with NYHA class II-IV heart failure, amlodipine was found not to cause any clinical deterioration, as measured by exercise tolerance, left ventricular ejection fraction and
clinical signs and symptoms.
A placebo-controlled study (PRAISE) designed to evaluate patients with NYHA class III-IV heart
failure receiving digoxin, diuretics and ACE inhibitors has shown that amlodipine did not lead to
an increase in risk of mortality or combined mortality and morbidity in patients with heart failure.
In a follow-up, long-term, placebo controlled study (PRAISE-2) of amlodipine in patients with
NYHA III and IV heart failure without clinical symptoms or objective findings suggestive of
underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics,
amlodipine had no effect on total or cardiovascular mortality. In this same population amlodipine
was associated with increased reports of pulmonary oedema despite no significant difference in
the incidence of worsening heart failure as compared to placebo.
Treatment to prevent heart attack trial (ALLHAT)
A randomized double-blind morbidity-mortality study called the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer
drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACEinhibitor)
as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/d in mild
to moderate hypertension.”
A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean
of 4.9 years. The patients had at least one additional CHD risk factor, including: previous
myocardial infarction or stroke (> 6 months prior to enrolment) or documentation of other
atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C < 35 mg/dL (11.6%), left
ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current
cigarette smoking (21.9%).
The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was
no significant difference in the primary endpoint between amlodipine-based therapy and
chlorthalidone-based therapy: RR 0.98 95% CI (0.90-1.07) p=0.65. Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was
significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% vs.
7.7%, RR 1.38, 95% CI [1.25-1.52] p<0.001). However, there was no significant difference in allcause
mortality between amlodipine-based therapy and chlorthalidone-based therapy (RR 0.96
95% CI [0.89-1.02] p=0.20).
Other information:
Two large randomised, controlled trials (ONTARGET (Ongoing Telmisartan Alone and in
combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs
Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an
angiotensin II receptor blocker.
ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular
disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA
NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.
These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes
and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension
as compared to monotherapy was observed. Given their similar pharmacodynamic properties,
these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.
ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly
in patients with diabetic nephropathy.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease
Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an
ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and
chronic kidney disease, cardiovascular disease, or both. The study was terminated early because
of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically
more frequent in the aliskiren group than in the placebo group and adverse events and serious  adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more
frequently reported in the aliskiren group than in the placebo group.

Following oral intake of Olneda, peak plasma concentrations of olmesartan and amlodipine are
reached at 1.5 – 2 h and 6 – 8 hours, respectively. The rate and extent of absorption of the two
active substances from Olneda are equivalent to the rate and extent of absorption following intake
of the two components as separate tablets. Food does not affect the bioavailability of olmesartan
and amlodipine from Olneda.
Olmesartan medoxomil (active ingredient of Olneda)
Absorption and distribution:
Olmesartan medoxomil is a prodrug. It is rapidly converted to the pharmacologically active
metabolite, olmesartan, by esterases in the gut mucosa and in portal blood during absorption from
the gastrointestinal tract. No intact olmesartan medoxomil or intact side chain medoxomil moiety
have been detected in plasma or excreta. The mean absolute bioavailability of olmesartan from a
tablet formulation was 25.6%.
The mean peak plasma concentration (Cmax) of olmesartan is reached within about 2 hours after
oral dosing with olmesartan medoxomil, and olmesartan plasma concentrations increase
approximately linearly with increasing single oral doses up to about 80 mg.
Food had minimal effect on the bioavailability of olmesartan and therefore olmesartan medoxomil
may be administered with or without food.
No clinically relevant gender-related differences in the pharmacokinetics of olmesartan have been
observed.
Olmesartan is highly bound to plasma protein (99.7%), but the potential for clinically significant
protein binding displacement interactions between olmesartan and other highly bound
coadministered active substances is low (as confirmed by the lack of a clinically significant interaction between olmesartan medoxomil and warfarin). The binding of olmesartan to blood cells
is negligible. The mean volume of distribution after intravenous dosing is low (16 – 29 L).
Biotransformation and elimination:
Total plasma clearance of olmesartan was typically 1.3 L/h (CV, 19%) and was relatively slow
compared to hepatic blood flow (ca 90 L/h). Following a single oral dose of 14C-labelled
olmesartan medoxomil, 10% – 16% of the administered radioactivity was excreted in the urine
(the vast majority within 24 hours of dose administration) and the remainder of the recovered
radioactivity was excreted in the faeces. Based on the systemic availability of 25.6%, it can be
calculated that absorbed olmesartan is cleared by both renal excretion (ca 40%) and hepato-biliary
excretion (ca 60%). All recovered radioactivity was identified as olmesartan. No other significant
metabolite was detected. Enterohepatic recycling of olmesartan is minimal. Since a large
proportion of olmesartan is excreted via the biliary route, use in patients with biliary obstruction
is contraindicated (see section 4.3).
The terminal elimination half life of olmesartan is between 10 and 15 hours after multiple oral
dosing. Steady state is reached after the first few doses and no further accumulation is evident after
14 days of repeated dosing. Renal clearance is approximately 0.5 – 0.7 L/h and is independent of
dose.
Drug interactions
Bile acid sequestering agent colesevelam:
Concomitant administration of 40 mg olmesartan medoxomil and 3750 mg colesevelam
hydrochloride in healthy subjects resulted in 28% reduction in Cmax and 39% reduction in AUC of
olmesartan. Lesser effects, 4% and 15% reduction in Cmax and AUC respectively, were observed
when olmesartan medoxomil was administered 4 hours prior to colesevelam hydrochloride.
Elimination half life of olmesartan was reduced by 50 – 52% irrespectively of whether
administered concomitantly or 4 hours prior to colesevelam hydrochloride (see section 4.5).

Amlodipine (active ingredient of Olneda)
Absorption and distribution:
After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels
between 6-12 hours post dose. Absolute bioavailability has been estimated to be between 64 and
80%. The volume of distribution is approximately 21 l/kg. In vitro studies have shown that
approximately 97.5% of circulating amlodipine is bound to plasma proteins.
The absorption of amlodipine is unaffected by the concomitant intake of food.
Biotransformation and elimination:
The terminal plasma elimination half life is about 35-50 hours and is consistent with once daily
dosing. Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of
the parent compound and 60% of metabolites excreted in the urine.
Olmesartan medoxomil and amlodipine (active ingredients of Olneda)
Special populations
Paediatric population (age below 18 years):
No pharmacokinetic data in paediatric patients are available.
Elderly (age 65 years or over):
In hypertensive patients, the olmesartan AUC at steady state is increased by ca 35% in elderly
people (65 – 75 years old) and by ca 44% in very elderly people (≥ 75 years old) compared with
the younger age group (see section 4.2). This may be at least in part related to a mean decrease in
renal function in this group of patients. The recommended dosage regimen for elderly people is,
however, the same, although caution should be exercised when increasing the dosage.
The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger
subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half life in elderly people. Increases in AUC and elimination half life in patients with
congestive heart failure were as expected for the patient age group in this study (see section 4.4).
Renal impairment:
In renally impaired patients, the olmesartan AUC at steady state increased by 62%, 82% and 179%
in patients with mild, moderate and severe renal impairment, respectively, compared to healthy
controls (see sections 4.2, 4.4).
Amlodipine is extensively metabolised to inactive metabolites. Ten percent of the substance is
excreted unchanged in the urine. Changes in amlodipine plasma concentration are not correlated
with the degree of renal impairment. In these patients, amlodipine may be administered at the
normal dosage. Amlodipine is not dialysable.
Hepatic impairment:
After single oral administration, olmesartan AUC values are 6% and 65% higher in mildly and
moderately hepatically impaired patients, respectively, than in their corresponding matched
healthy controls. The unbound fraction of olmesartan at 2 hours post-dose in healthy subjects, in
patients with mild hepatic impairment and in patients with moderate hepatic impairment is 0.26%,
0.34% and 0.41%, respectively. Following repeated dosing in patients with moderate hepatic
impairment, olmesartan mean AUC is again about 65% higher than in matched healthy controls.
Olmesartan mean Cmax values are similar in hepatically-impaired and healthy subjects.
Olmesartan medoxomil has not been evaluated in patients with severe hepatic impairment (see
sections 4.2, 4.4).
Very limited clinical data are available regarding amlodipine administration in patients with
hepatic impairment. The clearance of amlodipine is decreased and the half-life is prolonged in
patients with impaired hepatic function, resulting in an increase in AUC of about 40% – 60% (see
sections 4.2, 4.4).

Based on the non-clinical toxicity profile of each substance, no exacerbation of toxicities for the
combination is expected, because each substance has different targets, i.e. the kidneys for
olmesartan medoxomil and the heart for amlodipine.
In a 3-month, repeat-dose toxicity study of orally administered olmesartan medoxomil/amlodipine
in combination in rats the following alterations were observed: decreases in red blood cell countrelated
parameters and kidney changes both of which might be induced by the olmesartan
medoxomil component; alterations in the intestines (luminal dilatation and diffuse mucosal
thickening of the ileum and colon), the adrenals (hypertrophy of the glomerular cortical cells and
vacuolation of the fascicular cortical cells), and hypertrophy of the ducts in the mammary glands
which might be induced by the amlodipine component. These alterations neither augmented any
of the previously reported and existing toxicity of the individual agents nor induced any new
toxicity, and no toxicologically synergistic effects were observed.
Olmesartan medoxomil (active ingredient of Olneda)
In chronic toxicity studies in rats and dogs, olmesartan medoxomil showed similar effects to other
AT1 receptor antagonists and ACE inhibitors: raised blood urea (BUN) and creatinine; reduction
in heart weight; reduction of red cell parameters (erythrocytes, haemoglobin, haematocrit);
histological indications of renal damage (regenerative lesions of the renal epithelium, thickening
of the basal membrane, dilatation of the tubules). These adverse effects caused by the
pharmacological action of olmesartan medoxomil have also occurred in preclinical trials on other
AT1 receptor antagonists and ACE inhibitors and can be reduced by simultaneous oral
administration of sodium chloride. In both species, increased plasma renin activity and
hypertrophy/hyperplasia of the juxtaglomerular cells of the kidney were observed. These changes,
which are a typical effect of the class of ACE inhibitors and other AT1 receptor antagonists, would
appear to have no clinical relevance.

Like other AT1 receptor antagonists olmesartan medoxomil was found to increase the incidence
of chromosome breaks in cell cultures in vitro. No relevant effects were observed in several in
vivo studies using olmesartan medoxomil at very high oral doses of up to 2000 mg/kg. The overall
data of a comprehensive genotoxicity testing program suggest that olmesartan is very unlikely to
exert genotoxic effects under conditions of clinical use.
Olmesartan medoxomil was not carcinogenic, in a 2-year study in rats nor in two 6-month
carcinogenicity studies in transgenic mice.
In reproductive studies in rats, olmesartan medoxomil did not affect fertility and there was no
evidence of a teratogenic effect. In common with other angiotensin II antagonists, survival of
offspring was reduced following exposure to olmesartan medoxomil and pelvic dilatation of the
kidney was seen after exposure of the dams in late pregnancy and lactation. In common with other
antihypertensive agents, olmesartan medoxomil was shown to be more toxic to pregnant rabbits
than to pregnant rats, however, there was no indication of a fetotoxic effect.
Amlodipine (active ingredient of Olneda)
Reproductive toxicology
Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of
labour and decreased pup survival at dosages approximately 50 times greater than the maximum
recommended dosage for humans based on mg/kg.
Impairment of fertility
There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females
14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human
dose of 10 mg on a mg/m2 basis). In another rat study in which male rats were treated with
amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg,
decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases
in sperm density and in the number of mature spermatids and Sertoli cells.

Carcinogenesis, mutagenesis
Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to
provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity.
The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical
dose of 10 mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for
rats.
Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.
*Based on patient weight of 50 kg

Microcrystalline Cellulose PH113
Croscarmellose Sodium
Microcrystalline cellulose(Avicel PH 112)
Lactose Anhydrous DC Gr.
Colloidal Silicon Dioxide-Aerosil 200
Magnesium Stearate
Opadry II 85F18422 White (Used in 20 mg/5 mg)
Opadry II 85F565034 Brown (used in 20 mg/10 mg and 40 mg/10 mg strength)
Opadry II 85F32004Yellow (used in 40 mg/5 mg strength)

Not applicable.

2 years

Do not store above 30 °C.
Keep out of reach and sight of children.

Immediate Container: 3X10’s tablets packed in Alu – Alu blister
Secondary Container: Cartoon with PIL

No special requirements.